Impax to divest 10 products amid acquisition by Amneal

The Federal Trade Commission (FTC) is requiring Impax to divest rights and assets for ten products, as part of a settlement resolving charges that Amneal’s $1.45 billion acquisition would be anti-competitive.

Already registered?

For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk

More on this story

Americas

Masimo convinces judge that Apple took secrets—but it’s not enough

19 March 2026 Although the court agreed that the tech giant misappropriated some of Masimo’s information related to pulse oximetry technology, Apple is not barred from using it, says a California judge.

Americas

J&J unit targets former employee over alleged mass data theft

17 March 2026 Janssen seeks injunctive relief after a forensic review uncovers mass downloads of trade secrets spanning oncology, neuroscience and immunology portfolios.

Americas

Six Summit takeaways: In-person IP, agentic AI and ‘infollution’ risks

12 March 2026 The event unpacked how technology, litigation trends, and global events are adding complexity while also offering benefits for legal teams under pressure to reduce costs.

More features

Novartis bets $2bn on biologics as Xolair patents fade

WIPR debuts Global In-House Elite 2026

mRNA litigation: Who’s winning, who’s filing, and what’s next

Dechert boosts litigation bench with partner duo

UK court deals blow to Spanish pharma’s SPC bid for contraceptive

EPO reports record patent filings, but pharma and biotech lag

Part II: The race to replace semaglutide heats up

Part I: Ozempic goes generic as Novo’s key patent expires

Impax to divest 10 products amid acquisition by Amneal

More on this story

Editor's picks

Editor's picks

More features